Shares of Medivation Inc. (NASDAQ:MDVN) were up 19.7% during trading on Monday . The company traded as high as $80.67 and last traded at $80.40, with a volume of 39,531,610 shares traded. The stock had previously closed at $67.16.

A number of analysts recently commented on MDVN shares. Canaccord Genuity reiterated a “buy” rating and issued a $70.00 target price on shares of Medivation in a research note on Saturday, August 13th. Wedbush reiterated an “outperform” rating and issued a $66.00 target price on shares of Medivation in a research note on Friday, July 29th. Credit Suisse Group AG reiterated an “outperform” rating and issued a $63.00 target price on shares of Medivation in a research note on Wednesday, July 6th. JMP Securities cut shares of Medivation from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 10th. They noted that the move was a valuation call. Finally, Vetr cut shares of Medivation from a “hold” rating to a “sell” rating and set a $77.89 target price for the company. in a research note on Monday. One equities research analyst has rated the stock with a sell rating, eighteen have given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $76.96.

The stock has a 50 day moving average price of $64.36 and a 200-day moving average price of $53.13. The firm’s market capitalization is $13.32 billion.

Medivation (NASDAQ:MDVN) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. The business earned $206 million during the quarter, compared to analyst estimates of $214.52 million. During the same period in the previous year, the company earned $0.58 earnings per share. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. On average, equities research analysts forecast that Medivation Inc. will post $1.27 EPS for the current fiscal year.

In other news, SVP Andrew Kenneth William Powell sold 2,578 shares of the business’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $60.42, for a total value of $155,762.76. Following the completion of the sale, the senior vice president now directly owns 28,517 shares in the company, valued at approximately $1,722,997.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Other hedge funds and institutional investors recently modified their holdings of the company. BlackRock Advisors LLC increased its position in shares of Medivation by 3.3% in the fourth quarter. BlackRock Advisors LLC now owns 1,245,350 shares of the biopharmaceutical company’s stock worth $60,201,000 after buying an additional 40,001 shares during the last quarter. Advisors Asset Management Inc. increased its position in shares of Medivation by 16.6% in the fourth quarter. Advisors Asset Management Inc. now owns 25,952 shares of the biopharmaceutical company’s stock worth $1,255,000 after buying an additional 3,688 shares during the last quarter. I.G. Investment Management LTD. increased its position in shares of Medivation by 10.2% in the fourth quarter. I.G. Investment Management LTD. now owns 56,420 shares of the biopharmaceutical company’s stock worth $2,727,000 after buying an additional 5,200 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Medivation by 12.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 349,297 shares of the biopharmaceutical company’s stock worth $16,886,000 after buying an additional 38,893 shares during the last quarter. Finally, KBC Group NV increased its position in shares of Medivation by 98.7% in the fourth quarter. KBC Group NV now owns 32,177 shares of the biopharmaceutical company’s stock worth $1,556,000 after buying an additional 15,984 shares during the last quarter.

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.